Ryan Chaparian, Ph.D.

Ryan Chaparian, Ph.D. has a diverse and extensive work experience in the field of gene therapy and biopharmaceuticals. Ryan is currently working as a Scientist II at Taysha Gene Therapies. Prior to that, they worked at BioAgilytix as a Scientist, Gene and Cell Therapy, where they developed and validated qPCR/ddPCR assays for gene therapy product quantification and prepared study plans and reports for regulatory submissions. Ryan also optimized nucleic acid isolation/analysis processes for workflow efficiency.

Before joining BioAgilytix, Ryan was a Postdoctoral Scholar at Duke University School of Medicine, where they contributed to the development of antiviral AAV-based gene therapy and influenza vaccine platforms. Ryan conducted various experiments and analyses related to recombinant viruses, transgene expression, viral infectivity, and immune responses.

Ryan's earlier experiences include working as a Graduate Research Assistant at Indiana University Bloomington, where they focused on bacterial gene regulation and cellular signaling in pathogenic Vibrio bacteria. Ryan also worked as a Support Technician at Biomedical Research Models, gaining experience in animal husbandry and GLP-regulated labwork. Additionally, they served as a Laboratory Assistant at SelectX Pharmaceuticals.

Overall, Ryan Chaparian, Ph.D. has a strong background in gene therapy, molecular biology, and biopharmaceutical research, with a focus on developing therapeutic products and optimizing experimental processes.

Ryan Chaparian, Ph.D. pursued their education in the field of Biochemistry. Ryan received their Bachelor's Degree in Biochemistry from Purdue University in the period 2010 to 2014. Later, they attended Indiana University Bloomington where they completed their Doctor of Philosophy (Ph.D.) in Biochemistry from 2014 to 2020. In addition to their academic qualifications, Ryan Chaparian also obtained certifications in "Being an Effective Team Member" and "Critical Thinking and Problem Solving" from LinkedIn in July 2022.